

News Article downloaded from - <http://www.bioportfolio.com> on Sunday, November 22, 2009
Read [MultiVu Video Feed: Study in the New England Journal of Medicine Shows High Blood Pressure Drug Tekturna\(R\) Reduces Key Marker of Kidney Disease](#) on BioPortfolio.com
(http://www.bioportfolio.com/news/MultiVu_Video_Feed:_Study_in_the_New_England.html)

MultiVu Video Feed: Study in the New England Journal of Medicine Shows High Blood Pressure Drug Tekturna(R) Reduces Key Marker of Kidney Disease

Wednesday 4th of June 2008 17:02

BioPortfolio no longer holds the full text of this article in PDF form.

[Click Here To Read BioPortfolio's Web Page on MultiVu Video Feed: Study in the New England Journal of Medicine Shows High Blood Pressure Drug Tekturna\(R\) Reduces Key Marker of Kidney Disease](#)

- [MultiVu Video Feed: Study in the New England Journal of Medicine ...](#) 4 Jun 2008 ... *MultiVu Video Feed: Study in the New England Journal of Medicine Shows High Blood Pressure Drug Tekturna(R) Reduces Key Marker of Kidney ...*
<http://www.reuters.com/article/pressRelease/idUS213197+04-Ju...>
- [Rasilez , First-in-Class Direct Renin Inhibitor, Lowers High Blood ...](#) 3 Sep 2008 ... *Data from ALOFT study shows Rasilez reduces marker of heart failure ... in The New England Journal of Medicine, showed that Rasilez/Tekturna reduced albuminuria, a key indicator of kidney disease, by an additional 20% in type 2 diabetic patients with kidney disease and high blood pressure who were ...*
http://www.drugs.com/clinical_trials/rasilez-first-class-dir...
- [Rasilez, first-in-class direct renin inhibitor, provides greater ...](#) 11 Nov 2008 ... *New AGELESS data show Rasilez lowers systolic blood pressure by ... in The New England Journal of Medicine, showed that Rasilez/Tekturna reduced albuminuria, a key indicator of kidney disease, ... The ALLAY study demonstrated that Rasilez/Tekturna reduced left Animal Medicine. Veterinary Drugs ...*

http://www.drugs.com/clinical_trials/rasilez-first-class-dir...

- [Drugs.com - Clinical Trial Results Archive November 2007](#) November 6, Millennium Announces MLN1202 Significantly **Reduced Marker** of Systemic ... Direct Renin Inhibitor, **Reduces a Key Marker** of Heart Failure Severity November 15, **New England Journal of Medicine Study Shows** Erbitux November 28, **High Blood Pressure** May Heighten Effects of Alzheimer's **Disease** ...
http://www.drugs.com/clinical_trials_archive/November-2007.h...
- [Drugs.com - Clinical Trial Results Archive May 2008](#) May 5, **Kidney Disease** Substantially Worsens in a Fourth of African Americans Reports **Studies** Published in 'Science' Highlight **Key Role** of Phosphatidylserine May 22, Results Published in **New England Journal of Medicine Show** May 29, Cleviprex(TM) **Reduces** and Controls Acutely Elevated **Blood Pressure** in ...
http://www.drugs.com/clinical_trials_archive/May-2008.html...
- [Drugs.com - Clinical Trial Results Archive September 2007](#) Comprehensive **drug news** for both consumers and healthcare professionals. ... Peripheral Arterial **Disease** (PAD) Suffer **High Rates** of Heart Attack, Stroke, ...
September 6, The **New England Journal of Medicine** Publishes EURIDIS/ADONIS **Study** arterial stiffness, **reduced** by leading **blood pressure** medication Diovan®
...
http://www.drugs.com/clinical_trials_archive/September-2007....
- [Drugs.com - Clinical Trial Results Archive June 2007](#) June 15, Prexige **Study Shows** Significantly Less Impact on **Blood Pressure** Than for Neglected **Disease** Published in The **New England Journal of Medicine** ...
June 25, **New Study Shows** A1c **Reduced** Safely By Patients With Type 2 ... **Shows** Results on Safety, Tolerability and Glycemic **Markers** in Subjects **Tekturna**
...
http://www.drugs.com/clinical_trials_archive/June-2007.html...

Above results from a Google Custom Search Engine. [Search on BioPortfolio](#)

Via PR Newswire - PRNewswire.co.uk

Nothing in this document should be used in place of personal medical advice from your own qualified medical practitioner. See BioPortfolio.com [User Agreement](#)

Send comments and feedback to:

Peter Barfoot Managing Director, BioPortfolio Ltd.

UK Tel: (+44) 1300 321501

USA Voicemail and Fax: (+1) 415 680 2472

[Peter Barfoot peter.barfoot@bioportfolio.com](mailto:peter.barfoot@bioportfolio.com)

All rights reserved. All other trademarks recognized.

BioPortfolio Limited is registered in England & Wales at Stafford House, 10 Prince of Wales Road, Dorchester, Dorset, DT1 1PW, UK. No.3312883 VAT No. GB 744 6483 10

Copyright 1997-2009 - BioPortfolio Limited.

